Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

NCT ID: NCT03164564

Last Updated: 2025-10-09

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 3224 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-07
• Study Completion Date: 2026-10-17

Brief Summary

This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.

Detailed Description

The purpose of this study is to evaluate the safety and efficacy of the long-acting injectable integrase inhibitor cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in a population of sexually active HIV-uninfected women at risk for HIV.

This study will take place in three steps. Participants will be randomly assigned to one of two arms:

Arm A:

Step 1: Participants will receive daily oral CAB and TDF/FTC placebo for 5 weeks.

Step 2: Participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily TDF/FTC placebo beginning at Week 5.

Arm B:

Step 1: Participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks.

Step 2: Participants will receive daily TDF/FTC and intramuscular (IM) placebo injections at two time points 4 weeks apart and every 8 weeks thereafter beginning at Week 5.

Step 2 will continue until the last enrolled participant reaches approximately 76 weeks on Step 2 (Week 81 for the last enrolled participant).

In Step 3, all participants (Arms A and B) will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.

At the end of Step 3, all participants will then transition to locally available HIV prevention services, including services for PrEP, if available.

Study visits will occur at Day 0 and at Weeks 2 and 4 during Step 1. During Step 2, participants will attend up to 24 visits, depending on when they enroll in the study. Study visits will occur every 12 weeks during Step 3. Study visits may include physical examinations; blood, urine, and vaginal swab collection; risk reduction, adherence counseling, and contraception counseling.

HPTN 084-01 is a sub-study of HPTN 084. The purpose of this study is to examine the safety, tolerability, and acceptability of CAB LA for the prevention of HIV among adolescent females. Participants will receive oral CAB for 5 weeks, followed by 34 weeks on CAB LA, then quarterly visits for 48 weeks after final injection. All participants who have received at least one injection will be followed for 48 weeks after their last injection. Total study duration per participant will be approximately 21 months.

Conditions

HIV Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Arm A: CAB + Placebo TDF/FTC + CAB LA

During Step 1, participants will receive daily oral CAB and oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive injections of CAB LA at two time points 4 weeks apart and every 8 weeks thereafter and daily oral TDF/FTC placebo beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.

Group Type: EXPERIMENTAL

Oral CAB

Intervention Type: DRUG

CAB 30 mg tablet

Oral TDF/FTC

Intervention Type: DRUG

TDF/FTC 300 mg/200 mg fixed dose combination tablet

Placebo for oral TDF/FTC

Intervention Type: DRUG

Placebo tablets

CAB LA

Intervention Type: DRUG

600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle

Arm B: TDF/FTC + Placebo CAB + Placebo CAB LA

During Step 1, participants will receive daily TDF/FTC and oral CAB placebo for 5 weeks. In Step 2, participants will receive daily TDF/FTC and placebo for CAB LA injections at two times points 4 weeks apart and every 8 weeks thereafter beginning at Week 5. In Step 3, participants will receive daily TDF/FTC for up to 48 weeks, starting no later than 8 weeks after the last injection.

Group Type: ACTIVE_COMPARATOR

Oral TDF/FTC

Intervention Type: DRUG

TDF/FTC 300 mg/200 mg fixed dose combination tablet

Placebo for oral CAB

Intervention Type: DRUG

Placebo tablets

Placebo for CAB LA

Intervention Type: DRUG

Administered as one 3 mL intramuscular injection in the gluteal muscle

Interventions

Oral CAB

CAB 30 mg tablet

Intervention Type: DRUG

Oral TDF/FTC

TDF/FTC 300 mg/200 mg fixed dose combination tablet

Intervention Type: DRUG

Placebo for oral CAB

Placebo tablets

Intervention Type: DRUG

Placebo for oral TDF/FTC

Placebo tablets

Intervention Type: DRUG

CAB LA

600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle

Intervention Type: DRUG

Placebo for CAB LA

Administered as one 3 mL intramuscular injection in the gluteal muscle

Intervention Type: DRUG

Other Intervention Names

Cabotegravir; Tenofovir disoproxil fumarate/emtricitabine; Truvada; Cabotegravir long-acting injectable

Eligibility Criteria

Inclusion Criteria

• Born female
• 18-45 years at the time of screening
• Willing and able to provide informed consent
• Willing and able to undergo all required study procedures
• Non-reactive HIV test results at Screening and Enrollment. Note: HIV-uninfected, based on HIV test results obtained at Screening and just prior to randomization at the Enrollment visit. All HIV test results from the Screening visit must be obtained and must all be negative/non-reactive. This includes testing for acute HIV infection, which must be performed within 14 days of Enrollment. In addition, at least one HIV test result using blood drawn at the Enrollment visit must be obtained prior to randomization into the study and must be negative/non-reactive. Individuals who have one or more reactive or positive HIV test result(s) will not be enrolled, even if subsequent confirmatory testing indicates that they are not HIV-infected (see SSP Manual). Those with any enrollment HIV test result positive will proceed through the HIV algorithm per the SSP but will not be able to receive study product regardless of subsequent test results.
• Sexually active (i.e., vaginal intercourse on a minimum of two separate days in the 30 days prior to Screening)
• Score of greater than or equal to 5 using a modified VOICE risk score
• No plans to re-locate or travel away from the site for greater than or equal to 8 consecutive weeks during study participation
• Creatinine clearance of greater than or equal to 60 mL/min (using Cockcroft-Gault equation) (use sex at birth for calculation)

• Although not protocol exclusionary, sites should carefully consider the advisability of enrolling participants with calculated creatinine clearance between 60-70 mL/min, as limited changes in creatinine clearance during study conduct will lead to protocol-mandated product holds and may alter the risk-benefit considerations of study participation
• Hepatitis B virus (HBV) surface antigen (HBsAg) negative and accepts vaccination
• Alanine aminotransferase (ALT) less than 2 x upper limit of normal (ULN) and total bilirubin (Tbili) less than or equal to 2.5 x ULN
• HCV antibody negative
• If of reproductive potential (defined as pre-menopausal women who have not had a sterilization procedure per self-report, such as hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy), must have a negative beta human chorionic gonadotropin (βHCG) pregnancy test (sensitivity of less than or equal to 25 mIU/mL) performed (and results known) on the same day as and before initiating the protocol-specified study product(s) at Enrollment.
• Have documented evidence of surgical sterilization, OR documented evidence of no uterus (e.g., hysterectomy), OR must agree to use a reliable form of long acting contraception, during the trial and for 52 weeks after stopping the long acting injectable, or 30 days after stopping oral study product, from the list below:

• Intrauterine device (IUD) or intrauterine system (IUS) that meets less than 1% failure rate as stated in the product label
• Hormone-based contraceptive that meets less than 1% failure rate when used consistently and correctly as stated in the product label (implants or injectables only; this excludes combined oral contraception)
• No medical condition that, in the opinion of the study investigator, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records)
• No alcohol or substance use that, in the opinion of the study investigator, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical history and examination or in available medical records)

Exclusion Criteria

• One or more reactive HIV test results at Screening or Enrollment, even if HIV infection is not confirmed
• Pregnant or currently breastfeeding, or intends to become pregnant and/or breastfeed during the study
• Co-enrollment in any other HIV interventional research study (provided by self-report or other available documentation), with one exception: IMPAACT 2026 (co-enrollment in IMPAACT 2026 is permitted for participants who become pregnant)
• Current or past enrollment in an HIV vaccine or broadly neutralizing antibody trial
• Current or chronic history of liver disease (e.g., non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy)
• History of seizure disorder, per self-report
• Clinically significant cardiovascular disease, as defined by history/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease
• Inflammatory skin conditions that compromise the safety of IM injections, per the discretion of the Investigator of Record (IoR). Mild skin conditions may not be exclusionary at the discretion of the IoR or designee
• Has a tattoo or other dermatological condition overlying the buttock region which in the opinion of the IoR or designee may interfere with interpretation of injection site reactions (ISRs)
• Coagulopathy (primary or iatrogenic) which would contraindicate IM injection
• Active or planned use of prohibited medications as described in the Investigator Brochure (IB) or listed in the Study Specific Procedures Manual (SSP) (provided by self-report, or obtained from medical history or medical records)
• Known or suspected allergy to study product components (active or placebo), including egg or soy products (egg and soy products are contained in Intralipid)
• If potentially able to conceive, unwilling to adhere to long acting contraception (IUD/IUS, injection, or implant) with a less than 1% failure rate when used consistently and correctly as stated in the product package insert/ manufacturer's guidelines

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sinead Delany-Moretlwe, PhD, DTM&H

Role: STUDY_CHAIR

Wits Reproductive Health and HIV Institute CRS (WRHI CRS)

Mina Hosseinipour, MD, MPH

Role: STUDY_CHAIR

University of North Carolina (UNC) Project-Malawi, Tidziwe Centre

Locations

Gaborone CRS

Gaborone, South-East District, Botswana

Eswatini Prevention Center CRS

Mbabane, , Eswatini

Kisumu Crs

Kisumu, Nyanza, Kenya

Malawi CRS

Lilongwe, Central Region, Malawi

Blantyre CRS

Blantyre, , Malawi

Soweto HPTN CRS

Johannesburg, Gauteng, South Africa

Ward 21 CRS

Johannesburg, Gauteng, South Africa

Botha's Hill CRS

Durban, KwaZulu-Natal, South Africa

Isipingo CRS

Isipingo, KwaZulu-Natal, South Africa

Verulam CRS

Verulam, KwaZulu-Natal, South Africa

Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS

Cape Town, Western Cape, South Africa

Emavundleni CRS

Cape Town, Western Cape, South Africa

UVRI-IAVI HIV Vaccine Program LTD. CRS

Entebbe, , Uganda

Baylor-Uganda CRS

Kampala, , Uganda

MU-JHU Research Collaboration (MUJHU CARE LTD) CRS

Kampala, , Uganda

Zengeza CRS

Chitungwiza, Mashonaland East Province, Zimbabwe

Seke South CRS

Chitungwiza, , Zimbabwe

St Mary's CRS

Chitungwiza, , Zimbabwe

Milton Park CRS

Harare, , Zimbabwe

Spilhaus CRS

Harare, , Zimbabwe

Countries

Botswana; Eswatini; Kenya; Malawi; South Africa; Uganda; Zimbabwe

References

Marzinke MA, Han K, Hanscom B, Guo X, Piwowar-Manning E, Hendrix CW, Rose S, Spooner E, Mathew C, Innes S, Sekabira R, Mutambanengwe M, Rooney JF, Rinehart AR, Adeyeye A, Cohen MS, Hosseinipour M, Ford SL, Delany-Moretlwe S. Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084. Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0099424. doi: 10.1128/aac.00994-24. Epub 2024 Sep 23.

Reference Type: DERIVED

PMID: 39311597 (View on PubMed)

Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC; HPTN 084 study group. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1.

Reference Type: DERIVED

PMID: 35378077 (View on PubMed)

Scarsi KK. Chasing the cabotegravir tail: implications for prevention. Lancet HIV. 2020 Jul;7(7):e451-e453. doi: 10.1016/S2352-3018(20)30165-X. Epub 2020 Jun 1. No abstract available.

Reference Type: DERIVED

PMID: 32497490 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

38070

Identifier Type: REGISTRY

Identifier Source: secondary_id

HPTN 084

Identifier Type: -

Identifier Source: org_study_id